TAUNTON, UNITED KINGDOM--November 19, 2009--Researched by Protel Associates Limited in alliance with Industrial Info Europe (Galway, Ireland)--The United Kingdom's use of alternative energy sources is increasing at a rapid pace. In the biofuels market, feedstock prices have fallen to levels that have enabled producers to reconsider a number of projects previously placed on hold. Large grain surpluses have also reduced concerns regarding using food as fuel: Vivergo Fuels Limited (Hull), the joint venture between British Sugar Group (London), BP plc (NYSE:BP) (London) and DuPont (NYSE:DD) (Wilmington, Delaware), is now believed to be a considering a second £200 million ($335 million) grain-to-bioethanol production plant; Total SA's (NYSE:TOT) (Paris) Lindsey refinery, the third-largest oil refinery in the U.K., is currently considering constructing a new £30 million ($50 million) facility at the Immingham site to produce bioethanol for on-site blending with petrol. Additionally, major airports including Heathrow, East Midlands Airport, and Manchester Airport are pursuing biomass power solutions to reduce their carbon footprints.
Chicago, IL – November 19, 2009 – Zacks Equity Research highlights CPFL Energia (CPL) as the Bull of the Day and The Medicines Company (MDCO) the Bear of the Day. In addition, Zacks Equity Research provides analysis on Eastman Chemical Co.(EMN), Dow Chemical Company (DOW) and Dupont (DD).
We are maintaining our Outperform rating on CPFL Energia (CPL). The company posted in-line results for the third quarter of 2009, despite non-recurring items.
The company's outlook for the medium-term remains positive, mainly considering the more relaxed monetary policy in Brazil and the growing demand for electricity, even though there is the still-difficult business environment around the world.
Finally, CPL has a solid dividend payout and its valuation appears to be highly attractive, mainly considering the noncyclical nature of the company.
The Medicines Company’s (MDCO) third-quarter loss per share of 6 cents missed the Zacks Consensus Estimate of a loss of 5 cents. Although Angiomax continues to contribute significantly to revenues, we are concerned about the product losing exclusivity in the U.S. in September 2010.
The entry of generics would be devastating for the company. Therefore, the onus is on management to acquire and develop the next generation of products to drive the top-line. One of those products was expected to be Cangrelor. However, the failure of the phase III CHAMPION program was a significant setback.
Meanwhile, the Cleviprex sales ramp has also been slow. We recommend avoiding the name until we gain more visibility on the Angiomax patent situation, the Cleviprex ramp and the future of Cangrelor and Oritavancin.
Eastman Chemical Co. (EMN) has raised its full year 2009 earnings guidance to $3.50 per share from the initial guidance of $2 to $3 per share, driven by an expected strong growth in its core business. The company is hoping to deliver about 20% or over $6 per share growth in annual earnings by 2012, as the economy recovers completely.
The Zacks Consensus Estimate is pegged at $3.22 for 2009 and at 93 cents for the fourth quarter. Recently, Eastman’s close peers, Dow Chemical Company (DOW) and Dupont (DD) have also predicted strong growth in earnings.
Eastman stands to benefit from its business restructuring and cost-cutting measures, which are expected to result in cost savings of more than $200 million for the full year 2009. Eastman’s earnings of $1.38 per share in the third quarter of 2009 had bettered the Zacks Consensus Estimate of $1.13 per share helped by lower costs.
The company managed margins by reducing its operating costs. However, lower selling prices and volumes across all major segments resulted in a 21% year-over-year fall in Eastman’s top line of $1.3 billion for the quarter. Eastman’s core businesses, including Coatings, Adhesives, Specialty Polymers and Inks, Fibers, Performance Chemicals and Intermediates as well as Specialty Plastics suffered on weak demand from the automotive, building and construction, and packaging markets.
Every day, the analysts at Zacks Equity Research select two stocks that are likely to outperform (Bull) or underperform (Bear) the markets over the next 3-6 months.
About the Analyst Blog
Updated throughout every trading day, the Analyst Blog provides analysis from Zacks Equity Research about the latest news and events impacting stocks and the financial markets.
About Zacks Equity Research
Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.
Continuous analyst coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.
Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978 by Leonard Zacks. As a PhD in mathematics Len knew he could find patterns in stock market data that would lead to superior investment results. Amongst his many accomplishments was the formation of his proprietary stock picking system; the Zacks Rank, which continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros at http://at.zacks.com/?id=5509.
Disclaimer: Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security.
Contact:
Mark Vickery
Web Content Editor
312-265-9380
Visit: www.zacks.com
Eastman Chemical Co. (EMN) has raised its full year 2009 earnings guidance to $3.50 per share from the initial guidance of $2 to $3 per share, driven by an expected strong growth in its core business. The company is hoping to deliver about 20% or over $6 per share growth in annual earnings by 2012, [...]
Eastman Chemical Co. (EMN) has raised its full year 2009 earnings guidance to $3.50 per share from the initial guidance of $2 to $3 per share, driven by an expected strong growth in its core business. The company is hoping to deliver about 20% or over $6 per share growth in annual earnings by 2012, as the economy recovers completely.
The Zacks Consensus Estimate is pegged at $3.22 for 2009 and at 93 cents for the fourth quarter. Recently, Eastman’s close peers, Dow Chemical Company (DOW) and Dupont (DD) have also predicted strong growth in earnings.
Eastman stands to benefit from its business restructuring and cost-cutting measures, which are expected to result in cost savings of more than $200 million for the full year 2009. Eastman’s earnings of $1.38 per share in the third quarter of 2009 had bettered the Zacks Consensus Estimate of $1.13 per share helped by lower costs.
The company managed margins by reducing its operating costs. However, lower selling prices and volumes across all major segments resulted in a 21% year-over-year fall in Eastman’s top line of $1.3 billion for the quarter. Eastman’s core businesses, including Coatings, Adhesives, Specialty Polymers and Inks, Fibers, Performance Chemicals and Intermediates as well as Specialty Plastics suffered on weak demand from the automotive, building and construction, and packaging markets.
Tennessee-based Eastman, which makes chemicals, plastics and fibers used in everything from paints to furniture, expects to benefit from a better product mix and cost reduction measures in the fourth quarter of 2009. However, the company expects volatility in raw material and energy costs and a decline in sales volume due to normal seasonality having a negative affect on the upcoming quarter.
Eastman expects the growth in earnings investments in sustainable products and emerging markets. The company is eyeing the cigarettes market, which is witnessing high growth on the back of strong demand from Russia and China. Strong demand for cigarettes will help earnings in the company's fibers unit, which also produces base materials for clothing. Eastman produces acetate tow, used to make filters for cigarettes. In the Performance Polymer segment, Eastman is expecting operating earnings of $25 to $50 million by monetizing IntegRex technology investment through licensing.
Biotech investors interested in seeing more details about these companies and a full list of their related stories can do so by typing the stock ticker symbol into the Stock Quotes box on the right side of the page.Applied Nanoscience Inc. (ANI) (PINKSHEETS:APNN), a nanotechnology-based filtration company, today issued a progress report to its investors relating to progress in commercializing the disposable NanoFense™ Protective Face Mask, designed to offer superior protection against a broad spectrum of harmful virus, bacteria and fungi.Amarin Corp. (NASDAQ:AMRN), a clinical stage pharmaceutical company with R&D operations based in Mystic, Conn., has joined SAFE-BioPharma Association, the non-profit association that created and manages the global SAFE-BioPharma® digital identity and signature standard for the pharmaceutical and healthcare industries.Adolor Corporation (Nasdaq:ADLR) announced the initiation of clinical testing of ADL7445, its proprietary, oral mu opioid receptor antagonist for the treatment of Opioid Bowel Dysfunction (OBD).Abbott (NYSE:ABT) announced a definitive agreement to acquire the global rights to PanGenetics BV's PG110 fully humanized antibody to Nerve Growth Factor (NGF), expanding the company's pain care portfolio and leveraging its expertise in biologics. Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, is providing an update on its RNAi pipeline, platform, and technology at its R&D Day being held in New York today.CellCyte Genetics Corporation (OTC:CCYG) announced the appointment of Dr. Douglas Cerretti as Chief Science Officer and Director of Business Development effective November 1, 2009.DuPont (NYSE:DD) and BSES Limited announced a research, development and commercialization alliance to improve productivity and use of sugarcane varieties.Edwards Lifesciences Corporation (NYSE:EW), the global leader in the science of heart valves and hemodynamic monitoring, announced The Edwards Lifesciences Fund is granting $1.8 million to 107 nonprofit organizations as part of its fifth annual grant cycle. This fund is a donor-advised fund of the Vanguard Charitable Endowment Program.Inovio Biomedical Corporation (NYSE:INO), a leader in DNA vaccine design, development and delivery, announced the company will highlight its technology at two worldwide vaccine conferences next week. Dr. David Weiner, Chair of Inovio’s Scientific Advisory Board, and Niranjan Sardesai, Senior Vice President, SVP, Research and Development will speak on Inovio’s DNA vaccine development.Inhibitex, Inc. (Nasdaq:INHX), announced Russell H. Plumb, president and chief executive officer, will present an overview of the company and its pipeline of differentiated antiviral compounds at the Lazard Capital Markets 6th Annual Healthcare Conference at the St. Regis Hotel in New York City on Tuesday, November 17, 2009 at 1:40 p.m. Eastern Time.Luna Innovations Incorporated (NASDAQ:LUNA), a company focusing on sensing & instrumentation and pharmaceutical nanomedicines, today announced its financial results for the quarter ended September 30, 2009.Medtronic, Inc. (NYSE:MDT) announced the kick-off of an educational campaign aimed at raising awareness among women of overactive bladder (OAB), a serious condition that can severely impact patients’ lives.Mach One Corporation (OTC:MNCN), a rapidly growing, innovative, global wellness solutions company, announced it has completed the first tranche of its investment in PanTheryx, Inc., as stipulated in a recent Letter of Understanding signed in August 2009.Millipore Corporation (NYSE:MIL) a leading provider of technologies, tools and services for the global life science industry has been named “Corporate Citizen of the Year” by the New England Clean Energy Council.NeoGenomics, Inc. (OTC:NGNM) announced it will present at the Lazard Capital Markets 6th Annual Healthcare Conference being held November 17-18, 2009, at the St. Regis, New York Hotel in New York City.Nutra Pharma Corp. (OTC:NPHC), a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), has announced it plans to begin the drug registration process in Brazil and Colombia for its over-the-counter (OTC) pain reliever.Nile Therapeutics, Inc. (NASDAQ:NLTX), a company focused on the development of novel therapeutics for heart failure patients, announced its third quarter financial results for 2009.For the fiscal year ending June 30th, 2009, PD-Rx (Pink Sheets: PDRX) set record sales of $26.9 million over last year's sales figures of $26.4 million, reporting a net increase in sales of $493,230.PharmAthene, Inc. (NYSE:PIP), a biodefense company developing medical countermeasures against biological and chemical threats, reported financial and operational results for the third quarter and nine months ended September 30, 2009.Repros Therapeutics Inc. (Nasdaq:RPRX) announced it has elected Dr. Jaye Thompson to its Board of Directors, and as a member of the Board’s Audit Committee, effective immediately.Shire plc (Nasdaq:SHPGY), the global specialty biopharmaceutical company, announced findings from a post hoc analysis examining emotional lability from Phase 3 study data with Vyvanse®.In this study, Vyvanse demonstrated significant improvement in Attention-Deficit/Hyperactivity Disorder (ADHD) symptoms as measured by the ADHD Rating Scale IV (ADHD-RS IV) and Connors' Parent Rating Scale-Revised Short (CPRS-RS) in children with ADHD aged 6 to 12 years.ULURU Inc. (NYSE:ULU), a specialty pharmaceutical company focused on the development of a portfolio of wound management and oral care products, announced it has entered into definitive agreements to sell 10,714,467 shares of its common stock at a price per share of $0.14 pursuant to a registered direct offering to institutional investors, resulting in gross proceeds of approximately $1.5 million.
US stocks finished mixed on Tuesday as investors took a breather after Monday's sharp rally which pushed the Dow Jones industrial average to its highest level this year.[More...]
Companies featured in this segment: Jacobs Engineering Group Incorporated (NYSE:JEC), Sasol Limited (NYSE:SSL), OAO Gazprom (OTC:OGZPY), Pristine Power Incorporated (TSX:PPX), Ford Motor Company (NYSE:F), BP plc (NYSE:BP), DuPont (NYSE:DD), Total SA’s (NYSE:TOT), Jacobs Engineering (NYSE:JEC), VT Group (LSE:VTG)
Companies featured in this segment: RWE AG (OTC:RWEOY), E.ON AG (OTC:EONGY), Areva SA (EPA:CEI), Electricite de France SA (EPA:EDF), Scottish And Southern Energy plc (OTC:SSEZY), Wal-Mart Stores Incorporated’s (NYSE:WMT), Enterprise Products Partners LP (NYSE:EPD), Shell (NYSE:RDS.A), Exxon Mobile (NYSE:XOM), Valero’s (NYSE:VLO), ConocoPhillips’ (NYSE:COP), Alabama Power Company’s (NYSE:ALM), DuPont’s (NYSE:DD), Gulf Power Company’s (NYSE:GUL), Mississippi Power Company’s (NYSE:MPJ)
Companies featured in this segment: Duke Energy Corporation (NYSE:DUK), DuPont (NYSE:DD), American Electric Power Company (NYSE:AEP), Cairn India Limited (BSE:532792), Oil & Natural Gas Corporation Limited (BSE:500312), Hindustan Petroleum Corporation Limited (BSE:500104), Mangalore Refinery & Petrochemicals Limited (BSE:500109), Iberdrola SA (MCE:IBE), Indian Oil Corporation Limited (BSE:530965)
Companies featured in this segment: ABB Limited (NYSE:ABB), Dow Chemical Company (NYSE:DOW), Eastman Chemical Company (NYSE:EMN), Siemens AG (NYSE:SI), TransCanada Corporation (NYSE:TRP), National Grid plc (NYSE:NGG), Royal Shell (NYSE:RDS.A), E.I. du Pont de Nemours & Company (NYSE:DD), BASF SE (OTC:BASFY), E.ON AG (OTC:EONGY), GDF Suez (OTC:GDFZY)
All News |
Breaking News |
Featured Stories